![]() They’re hoping to eventually help guide imaging professionals in the development of targeted therapies through genetic and molecular profiling, the announcement noted. In his new role, Hoppin will now focus on synergizing the three disparate companies under one precision medicine umbrella. “This is an exciting time for Invicro, Ambry and Konica Minolta Precision Medicine (KMPM), as we are all working together to support the medical research community through integrated AI technology platforms that allow molecular-level testing and analysis offering insights to advance translational medicine.” “It has been an extreme honor to serve as Invicro’s CEO since co-founding the company in 2008,” Hoppin said in a statement. The initiative will now work to further its goals through advancements in genetics, imaging and digital pathology, the company noted in a Dec. ![]() KM first acquired both startup Invicro and Ambry Genetics Corporation in 2017 to help speed up its goals of accelerating healthcare’s move to precision medicine. Following his shift to a new role, Matthew Silva, PhD, is taking over as chief executive of Invicro, which Hoppin originally founded. Hoppin had been serving as president and CEO of Invicro, a Boston-based offshoot of KM that works in the development of precision drugs. Tokyo-based technology and imaging company Konica Minolta (KM) has announced the appointment of Jack Hoppin, PhD, as president of its precision medicine initiatives.
0 Comments
Leave a Reply. |